Insider Transaction Report for Margaret McGlynn

Margaret McGlynn, a director at AMICUS THERAPEUTICS, INC. (FOLD), reported the disposition of 94,631 shares of Common Stock at $14.50 per share on April 27, 2026. This transaction, along with the cancellation and conversion of various stock options into cash payments, occurred in connection with the acquisition of the Issuer by BioMarin Pharmaceutical Inc. The options, all of which were fully vested, were converted into the right to receive a cash payment based on the difference between $14.50 per share and their respective exercise prices. All post-transaction share ownership for Ms. McGlynn is reported as zero.